Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Director Donald D Belcher sold 4,176 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $ 7.00, for a total value of $ 29,232.00. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares after opening at $6.89 moved to $6.98 on last trade day and at the end of the day closed at $6.85. Company price to sales ratio in past twelve months was calculated as 18.45and price to cash ratio as 6.77. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a positive weekly performance of 7.03%.
InterMune Inc (NASDAQ:ITMN) CEO Daniel G. Welch sold 60,432 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $34.76, for a total value of $2,100,616.32. Following the completion of the transaction, the chief executive officer now directly owns 98,106 shares of the company’s stock, valued at approximately $3,410,165. InterMune Inc (NASDAQ:ITMN) shares advanced 0.86% in last trading session and ended the day on $36.49 . ITMN return on equity ratio is recorded as -164.60% and its return on assets is -48.20%. InterMune Inc (NASDAQ:ITMN) yearly performance is 302.76%.
Cell Therapeutics Inc (NASDAQ:CTIC) EVP Louis Bianco sold 10,000 shares of the stock on the open market in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $2.91, for a total value of $29,100.00. Following the transaction, the executive vice president now directly owns 812,897 shares of the company’s stock, valued at approximately $2,365,530.Cell Therapeutics Inc (NASDAQ:CTIC) shares moved down -2.79% in last trading session and was closed at $2.79 while trading in range of $2.73 – $2.88- Cell Therapeutics Inc (NASDAQ:CTIC) year to date (YTD) performance is 46.07%.
Acceleron Pharma Inc (NASDAQ:XLRN) Director Jean George unloaded 215,644 shares of Acceleron Pharma stock on the open market in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $42.86, for a total value of $9,242,501.84.Acceleron Pharma Inc (NASDAQ:XLRN) weekly performance is -4.83%. On last trading day company shares ended up $32.69. Acceleron Pharma Inc (NASDAQ:XLRN) distance from 50-day simple moving average (SMA50) is -17.32%. Analysts mean target price for the company is $55.00.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) COO John Duncan Higgons unloaded 7,000 shares of Agios Pharmaceuticals stock on the open market in a transaction dated Thursday, May 1st. The stock was sold at an average price of $42.39, for a total value of $296,730.00. Following the sale, the chief operating officer now directly owns 205,090 shares of the company’s stock, valued at approximately $8,693,765.Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares after opening at $42.17moved to $42.29 on last trade day and at the end of the day closed at $40.78. Company price to sales ratio in past twelve months was calculated as 53.09and price to cash ratio as 8.12. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a negative weekly performance of -3.04%.